| Autor: |
Kunadian V; Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA., Zorkun C, Gibson WJ, Nethala N, Harrigan C, Palmer AM, Ogando KJ, Biller LH, Lord EE, Williams SP, Lew ME, Ciaglo LN, Buros JL, Marble SJ, Gibson CM |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2009 Jan; Vol. 27 (1), pp. 57-67. Date of Electronic Publication: 2008 Sep 03. |
| DOI: |
10.1007/s11239-008-0268-0 |
| Abstrakt: |
Potent antiplatelet and antithrombotic agents have significantly reduced mortality in the setting of acute coronary syndromes and percutaneous coronary intervention. However these agents are associated with increased bleeding which is in turn associated with adverse clinical outcomes. In many centers, transfusion is often used to correct for blood loss. Blood transfusion in the setting of acute coronary syndrome has been associated with adverse clinical outcomes including increased mortality. Transfusion associated microchimerism (TA-MC) is a newly recognized complication of blood transfusion. There is engraftment of the donor's hematopoietic stem cells in patients who then develop microchimerism. This article discusses the association of bleeding/blood transfusion with adverse outcomes and the potential role of TA-MC in clinical outcomes. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink